<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d444" origId="Doxepin"><sentence id="DrugDDI.d444.s0" origId="s0" text="Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called poor metabolizers);"><entity id="DrugDDI.d444.s0.e0" origId="s0.p0" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d444.s0.e1" origId="s0.p2" charOffset="21-30" type="drug" text="P450 2D6"/><entity id="DrugDDI.d444.s0.e2" origId="s0.p5" charOffset="63-67" type="drug" text="drug"/><entity id="DrugDDI.d444.s0.e3" origId="s0.p7" charOffset="110-134" type="drug" text="debrisoquin hydroxylase"/><pair id="DrugDDI.d444.s0.p0" e1="DrugDDI.d444.s0.e0" e2="DrugDDI.d444.s0.e1" interaction="false"/><pair id="DrugDDI.d444.s0.p1" e1="DrugDDI.d444.s0.e0" e2="DrugDDI.d444.s0.e2" interaction="false"/><pair id="DrugDDI.d444.s0.p2" e1="DrugDDI.d444.s0.e0" e2="DrugDDI.d444.s0.e3" interaction="false"/><pair id="DrugDDI.d444.s0.p3" e1="DrugDDI.d444.s0.e1" e2="DrugDDI.d444.s0.e2" interaction="false"/><pair id="DrugDDI.d444.s0.p4" e1="DrugDDI.d444.s0.e1" e2="DrugDDI.d444.s0.e3" interaction="false"/><pair id="DrugDDI.d444.s0.p5" e1="DrugDDI.d444.s0.e2" e2="DrugDDI.d444.s0.e3" interaction="false"/></sentence><sentence id="DrugDDI.d444.s1" origId="s1" text="reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available."><entity id="DrugDDI.d444.s1.e0" origId="s1.p22" charOffset="48-65" type="drug" text="P450 2D6 isozyme"/></sentence><sentence id="DrugDDI.d444.s2" origId="s2" text="Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses."><entity id="DrugDDI.d444.s2.e0" origId="s2.p33" charOffset="69-94" type="drug" text="tricyclic antidepressants"/></sentence><sentence id="DrugDDI.d444.s3" origId="s3" text="Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA)."><entity id="DrugDDI.d444.s3.e0" origId="s3.p41" charOffset="29-33" type="drug" text="drug"/><entity id="DrugDDI.d444.s3.e1" origId="s3.p43" charOffset="49-58" type="drug" text="P450 2D6"/><pair id="DrugDDI.d444.s3.p0" e1="DrugDDI.d444.s3.e0" e2="DrugDDI.d444.s3.e1" interaction="true"/></sentence><sentence id="DrugDDI.d444.s4" origId="s4" text="In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers."><entity id="DrugDDI.d444.s4.e0" origId="s4.p57" charOffset="21-26" type="drug" text="drugs"/><entity id="DrugDDI.d444.s4.e1" origId="s4.p60" charOffset="56-63" type="drug" text="isozyme"/><pair id="DrugDDI.d444.s4.p0" e1="DrugDDI.d444.s4.e0" e2="DrugDDI.d444.s4.e1" interaction="true"/></sentence><sentence id="DrugDDI.d444.s5" origId="s5" text="An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy."><entity id="DrugDDI.d444.s5.e0" origId="s5.p77" charOffset="112-117" type="drug" text="drugs"/></sentence><sentence id="DrugDDI.d444.s6" origId="s6" text="The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;"><entity id="DrugDDI.d444.s6.e0" origId="s6.p79" charOffset="4-9" type="drug" text="drugs"/><entity id="DrugDDI.d444.s6.e1" origId="s6.p82" charOffset="23-42" type="drug" text="cytochrome P450 2D6"/><entity id="DrugDDI.d444.s6.e2" origId="s6.p91" charOffset="96-105" type="drug" text="quinidine"/><pair id="DrugDDI.d444.s6.p0" e1="DrugDDI.d444.s6.e0" e2="DrugDDI.d444.s6.e1" interaction="false"/><pair id="DrugDDI.d444.s6.p1" e1="DrugDDI.d444.s6.e0" e2="DrugDDI.d444.s6.e2" interaction="false"/><pair id="DrugDDI.d444.s6.p2" e1="DrugDDI.d444.s6.e1" e2="DrugDDI.d444.s6.e2" interaction="false"/></sentence><sentence id="DrugDDI.d444.s7" origId="s7" text="cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide)."><entity id="DrugDDI.d444.s7.e0" origId="s7.p93" charOffset="0-10" type="drug" text="cimetidine"/><entity id="DrugDDI.d444.s7.e1" origId="s7.p100" charOffset="45-54" type="drug" text="P450 2D6"/><entity id="DrugDDI.d444.s7.e2" origId="s7.p102" charOffset="66-81" type="drug" text="antidepressants"/><entity id="DrugDDI.d444.s7.e3" origId="s7.p103" charOffset="83-97" type="drug" text="phenothiazines"/><entity id="DrugDDI.d444.s7.e4" origId="s7.p105" charOffset="131-142" type="drug" text="propafenone"/><entity id="DrugDDI.d444.s7.e5" origId="s7.p107" charOffset="147-157" type="drug" text="flecainide"/><pair id="DrugDDI.d444.s7.p0" e1="DrugDDI.d444.s7.e0" e2="DrugDDI.d444.s7.e1" interaction="false"/><pair id="DrugDDI.d444.s7.p1" e1="DrugDDI.d444.s7.e0" e2="DrugDDI.d444.s7.e2" interaction="false"/><pair id="DrugDDI.d444.s7.p2" e1="DrugDDI.d444.s7.e0" e2="DrugDDI.d444.s7.e3" interaction="false"/><pair id="DrugDDI.d444.s7.p3" e1="DrugDDI.d444.s7.e0" e2="DrugDDI.d444.s7.e4" interaction="false"/><pair id="DrugDDI.d444.s7.p4" e1="DrugDDI.d444.s7.e0" e2="DrugDDI.d444.s7.e5" interaction="false"/><pair id="DrugDDI.d444.s7.p5" e1="DrugDDI.d444.s7.e1" e2="DrugDDI.d444.s7.e2" interaction="false"/><pair id="DrugDDI.d444.s7.p6" e1="DrugDDI.d444.s7.e1" e2="DrugDDI.d444.s7.e3" interaction="false"/><pair id="DrugDDI.d444.s7.p7" e1="DrugDDI.d444.s7.e1" e2="DrugDDI.d444.s7.e4" interaction="false"/><pair id="DrugDDI.d444.s7.p8" e1="DrugDDI.d444.s7.e1" e2="DrugDDI.d444.s7.e5" interaction="false"/><pair id="DrugDDI.d444.s7.p9" e1="DrugDDI.d444.s7.e2" e2="DrugDDI.d444.s7.e3" interaction="false"/><pair id="DrugDDI.d444.s7.p10" e1="DrugDDI.d444.s7.e2" e2="DrugDDI.d444.s7.e4" interaction="false"/><pair id="DrugDDI.d444.s7.p11" e1="DrugDDI.d444.s7.e2" e2="DrugDDI.d444.s7.e5" interaction="false"/><pair id="DrugDDI.d444.s7.p12" e1="DrugDDI.d444.s7.e3" e2="DrugDDI.d444.s7.e4" interaction="false"/><pair id="DrugDDI.d444.s7.p13" e1="DrugDDI.d444.s7.e3" e2="DrugDDI.d444.s7.e5" interaction="false"/><pair id="DrugDDI.d444.s7.p14" e1="DrugDDI.d444.s7.e4" e2="DrugDDI.d444.s7.e5" interaction="false"/></sentence><sentence id="DrugDDI.d444.s8" origId="s8" text="While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition."><entity id="DrugDDI.d444.s8.e0" origId="s8.p111" charOffset="24-53" type="drug" text="serotonin reuptake inhibitors"/><entity id="DrugDDI.d444.s8.e1" origId="s8.p118" charOffset="69-79" type="drug" text="citalopram"/><entity id="DrugDDI.d444.s8.e2" origId="s8.p119" charOffset="81-93" type="drug" text="escitalopram"/><entity id="DrugDDI.d444.s8.e3" origId="s8.p120" charOffset="95-105" type="drug" text="fluoxetine"/><entity id="DrugDDI.d444.s8.e4" origId="s8.p121" charOffset="107-117" type="drug" text="sertraline"/><entity id="DrugDDI.d444.s8.e5" origId="s8.p123" charOffset="123-133" type="drug" text="paroxetine"/><entity id="DrugDDI.d444.s8.e6" origId="s8.p125" charOffset="143-152" type="drug" text="P450 2D6"/><pair id="DrugDDI.d444.s8.p0" e1="DrugDDI.d444.s8.e0" e2="DrugDDI.d444.s8.e1" interaction="false"/><pair id="DrugDDI.d444.s8.p1" e1="DrugDDI.d444.s8.e0" e2="DrugDDI.d444.s8.e2" interaction="false"/><pair id="DrugDDI.d444.s8.p2" e1="DrugDDI.d444.s8.e0" e2="DrugDDI.d444.s8.e3" interaction="false"/><pair id="DrugDDI.d444.s8.p3" e1="DrugDDI.d444.s8.e0" e2="DrugDDI.d444.s8.e4" interaction="false"/><pair id="DrugDDI.d444.s8.p4" e1="DrugDDI.d444.s8.e0" e2="DrugDDI.d444.s8.e5" interaction="false"/><pair id="DrugDDI.d444.s8.p5" e1="DrugDDI.d444.s8.e0" e2="DrugDDI.d444.s8.e6" interaction="false"/><pair id="DrugDDI.d444.s8.p6" e1="DrugDDI.d444.s8.e1" e2="DrugDDI.d444.s8.e2" interaction="false"/><pair id="DrugDDI.d444.s8.p7" e1="DrugDDI.d444.s8.e1" e2="DrugDDI.d444.s8.e3" interaction="false"/><pair id="DrugDDI.d444.s8.p8" e1="DrugDDI.d444.s8.e1" e2="DrugDDI.d444.s8.e4" interaction="false"/><pair id="DrugDDI.d444.s8.p9" e1="DrugDDI.d444.s8.e1" e2="DrugDDI.d444.s8.e5" interaction="false"/><pair id="DrugDDI.d444.s8.p10" e1="DrugDDI.d444.s8.e1" e2="DrugDDI.d444.s8.e6" interaction="false"/><pair id="DrugDDI.d444.s8.p11" e1="DrugDDI.d444.s8.e2" e2="DrugDDI.d444.s8.e3" interaction="false"/><pair id="DrugDDI.d444.s8.p12" e1="DrugDDI.d444.s8.e2" e2="DrugDDI.d444.s8.e4" interaction="false"/><pair id="DrugDDI.d444.s8.p13" e1="DrugDDI.d444.s8.e2" e2="DrugDDI.d444.s8.e5" interaction="false"/><pair id="DrugDDI.d444.s8.p14" e1="DrugDDI.d444.s8.e2" e2="DrugDDI.d444.s8.e6" interaction="false"/><pair id="DrugDDI.d444.s8.p15" e1="DrugDDI.d444.s8.e3" e2="DrugDDI.d444.s8.e4" interaction="false"/><pair id="DrugDDI.d444.s8.p16" e1="DrugDDI.d444.s8.e3" e2="DrugDDI.d444.s8.e5" interaction="false"/><pair id="DrugDDI.d444.s8.p17" e1="DrugDDI.d444.s8.e3" e2="DrugDDI.d444.s8.e6" interaction="false"/><pair id="DrugDDI.d444.s8.p18" e1="DrugDDI.d444.s8.e4" e2="DrugDDI.d444.s8.e5" interaction="false"/><pair id="DrugDDI.d444.s8.p19" e1="DrugDDI.d444.s8.e4" e2="DrugDDI.d444.s8.e6" interaction="false"/><pair id="DrugDDI.d444.s8.p20" e1="DrugDDI.d444.s8.e5" e2="DrugDDI.d444.s8.e6" interaction="false"/></sentence><sentence id="DrugDDI.d444.s9" origId="s9" text="The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved."/><sentence id="DrugDDI.d444.s10" origId="s10" text="Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other."/><sentence id="DrugDDI.d444.s11" origId="s11" text="Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary)."><entity id="DrugDDI.d444.s11.e0" origId="s11.p166" charOffset="120-130" type="drug" text="fluoxetine"/><entity id="DrugDDI.d444.s11.e1" origId="s11.p171" charOffset="175-192" type="drug" text="active metabolite"/><pair id="DrugDDI.d444.s11.p0" e1="DrugDDI.d444.s11.e0" e2="DrugDDI.d444.s11.e1" interaction="false"/></sentence><sentence id="DrugDDI.d444.s12" origId="s12" text="Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug."><entity id="DrugDDI.d444.s12.e0" origId="s12.p179" charOffset="19-44" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d444.s12.e1" origId="s12.p180" charOffset="50-55" type="drug" text="drugs"/><entity id="DrugDDI.d444.s12.e2" origId="s12.p184" charOffset="73-92" type="drug" text="cytochrome P450 2D6"/><entity id="DrugDDI.d444.s12.e3" origId="s12.p192" charOffset="156-180" type="drug" text="tricyclic antidepressant"/><entity id="DrugDDI.d444.s12.e4" origId="s12.p194" charOffset="194-198" type="drug" text="drug"/><pair id="DrugDDI.d444.s12.p0" e1="DrugDDI.d444.s12.e0" e2="DrugDDI.d444.s12.e1" interaction="true"/><pair id="DrugDDI.d444.s12.p1" e1="DrugDDI.d444.s12.e0" e2="DrugDDI.d444.s12.e2" interaction="false"/><pair id="DrugDDI.d444.s12.p2" e1="DrugDDI.d444.s12.e0" e2="DrugDDI.d444.s12.e3" interaction="false"/><pair id="DrugDDI.d444.s12.p3" e1="DrugDDI.d444.s12.e0" e2="DrugDDI.d444.s12.e4" interaction="false"/><pair id="DrugDDI.d444.s12.p4" e1="DrugDDI.d444.s12.e1" e2="DrugDDI.d444.s12.e2" interaction="false"/><pair id="DrugDDI.d444.s12.p5" e1="DrugDDI.d444.s12.e1" e2="DrugDDI.d444.s12.e3" interaction="false"/><pair id="DrugDDI.d444.s12.p6" e1="DrugDDI.d444.s12.e1" e2="DrugDDI.d444.s12.e4" interaction="false"/><pair id="DrugDDI.d444.s12.p7" e1="DrugDDI.d444.s12.e2" e2="DrugDDI.d444.s12.e3" interaction="false"/><pair id="DrugDDI.d444.s12.p8" e1="DrugDDI.d444.s12.e2" e2="DrugDDI.d444.s12.e4" interaction="false"/><pair id="DrugDDI.d444.s12.p9" e1="DrugDDI.d444.s12.e3" e2="DrugDDI.d444.s12.e4" interaction="false"/></sentence><sentence id="DrugDDI.d444.s13" origId="s13" text="Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required."><entity id="DrugDDI.d444.s13.e0" origId="s13.p198" charOffset="41-46" type="drug" text="drugs"/><entity id="DrugDDI.d444.s13.e1" origId="s13.p203" charOffset="98-122" type="drug" text="tricyclic antidepressant"/><pair id="DrugDDI.d444.s13.p0" e1="DrugDDI.d444.s13.e0" e2="DrugDDI.d444.s13.e1" interaction="false"/></sentence><sentence id="DrugDDI.d444.s14" origId="s14" text="It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6."><entity id="DrugDDI.d444.s14.e0" origId="s14.p219" charOffset="104-108" type="drug" text="drug"/><entity id="DrugDDI.d444.s14.e1" origId="s14.p224" charOffset="137-146" type="drug" text="P450 2D6"/><pair id="DrugDDI.d444.s14.p0" e1="DrugDDI.d444.s14.e0" e2="DrugDDI.d444.s14.e1" interaction="false"/></sentence><sentence id="DrugDDI.d444.s15" origId="s15" text="Doxepin is primarily metabolized by CYP2D6 (with CYP1A2  and  CYP3A4 as minor pathways)."><entity id="DrugDDI.d444.s15.e0" origId="s15.p225" charOffset="0-7" type="drug" text="Doxepin"/><entity id="DrugDDI.d444.s15.e1" origId="s15.p229" charOffset="36-42" type="drug" text="CYP2D6"/><entity id="DrugDDI.d444.s15.e2" origId="s15.p231" charOffset="62-68" type="drug" text="CYP3A4"/><pair id="DrugDDI.d444.s15.p0" e1="DrugDDI.d444.s15.e0" e2="DrugDDI.d444.s15.e1" interaction="false"/><pair id="DrugDDI.d444.s15.p1" e1="DrugDDI.d444.s15.e0" e2="DrugDDI.d444.s15.e2" interaction="false"/><pair id="DrugDDI.d444.s15.p2" e1="DrugDDI.d444.s15.e1" e2="DrugDDI.d444.s15.e2" interaction="false"/></sentence><sentence id="DrugDDI.d444.s16" origId="s16" text="Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly."><entity id="DrugDDI.d444.s16.e0" origId="s16.p237" charOffset="28-34" type="drug" text="CYP2D6"/><entity id="DrugDDI.d444.s16.e1" origId="s16.p240" charOffset="42-51" type="drug" text="quinidine"/><entity id="DrugDDI.d444.s16.e2" origId="s16.p241" charOffset="63-92" type="drug" text="serotonin reuptake inhibitors"/><entity id="DrugDDI.d444.s16.e3" origId="s16.p246" charOffset="143-150" type="drug" text="doxepin"/><pair id="DrugDDI.d444.s16.p0" e1="DrugDDI.d444.s16.e0" e2="DrugDDI.d444.s16.e1" interaction="true"/><pair id="DrugDDI.d444.s16.p1" e1="DrugDDI.d444.s16.e0" e2="DrugDDI.d444.s16.e2" interaction="false"/><pair id="DrugDDI.d444.s16.p2" e1="DrugDDI.d444.s16.e0" e2="DrugDDI.d444.s16.e3" interaction="false"/><pair id="DrugDDI.d444.s16.p3" e1="DrugDDI.d444.s16.e1" e2="DrugDDI.d444.s16.e2" interaction="false"/><pair id="DrugDDI.d444.s16.p4" e1="DrugDDI.d444.s16.e1" e2="DrugDDI.d444.s16.e3" interaction="true"/><pair id="DrugDDI.d444.s16.p5" e1="DrugDDI.d444.s16.e2" e2="DrugDDI.d444.s16.e3" interaction="true"/></sentence><sentence id="DrugDDI.d444.s17" origId="s17" text="The extent of interaction depends on the variability of effect on CYP2D6."><entity id="DrugDDI.d444.s17.e0" origId="s17.p255" charOffset="66-72" type="drug" text="CYP2D6"/></sentence><sentence id="DrugDDI.d444.s18" origId="s18" text="The clinical significance of this interaction with doxepin has not been systematically evaluated."><entity id="DrugDDI.d444.s18.e0" origId="s18.p258" charOffset="51-58" type="drug" text="doxepin"/></sentence><sentence id="DrugDDI.d444.s19" origId="s19" text="MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors."><entity id="DrugDDI.d444.s19.e0" origId="s19.p264" charOffset="0-14" type="drug" text="MAO Inhibitors"/><entity id="DrugDDI.d444.s19.e1" origId="s19.p274" charOffset="112-117" type="drug" text="drugs"/><entity id="DrugDDI.d444.s19.e2" origId="s19.p275" charOffset="123-137" type="drug" text="MAO inhibitors"/><pair id="DrugDDI.d444.s19.p0" e1="DrugDDI.d444.s19.e0" e2="DrugDDI.d444.s19.e1" interaction="false"/><pair id="DrugDDI.d444.s19.p1" e1="DrugDDI.d444.s19.e0" e2="DrugDDI.d444.s19.e2" interaction="false"/><pair id="DrugDDI.d444.s19.p2" e1="DrugDDI.d444.s19.e1" e2="DrugDDI.d444.s19.e2" interaction="true"/></sentence><sentence id="DrugDDI.d444.s20" origId="s20" text="Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN."><entity id="DrugDDI.d444.s20.e0" origId="s20.p277" charOffset="11-25" type="drug" text="MAO inhibitors"/><entity id="DrugDDI.d444.s20.e1" origId="s20.p284" charOffset="117-125" type="drug" text="SINEQUAN"/><pair id="DrugDDI.d444.s20.p0" e1="DrugDDI.d444.s20.e0" e2="DrugDDI.d444.s20.e1" interaction="true"/></sentence><sentence id="DrugDDI.d444.s21" origId="s21" text="The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved."><entity id="DrugDDI.d444.s21.e0" origId="s21.p292" charOffset="71-84" type="drug" text="MAO inhibitor"/></sentence><sentence id="DrugDDI.d444.s22" origId="s22" text="Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants."><entity id="DrugDDI.d444.s22.e0" origId="s22.p306" charOffset="0-10" type="drug" text="Cimetidine"/><entity id="DrugDDI.d444.s22.e1" origId="s22.p308" charOffset="12-22" type="drug" text="Cimetidine"/><entity id="DrugDDI.d444.s22.e2" origId="s22.p316" charOffset="136-161" type="drug" text="tricyclic antidepressants"/><pair id="DrugDDI.d444.s22.p0" e1="DrugDDI.d444.s22.e0" e2="DrugDDI.d444.s22.e1" interaction="false"/><pair id="DrugDDI.d444.s22.p1" e1="DrugDDI.d444.s22.e0" e2="DrugDDI.d444.s22.e2" interaction="false"/><pair id="DrugDDI.d444.s22.p2" e1="DrugDDI.d444.s22.e1" e2="DrugDDI.d444.s22.e2" interaction="true"/></sentence><sentence id="DrugDDI.d444.s23" origId="s23" text="Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated."><entity id="DrugDDI.d444.s23.e0" origId="s23.p317" charOffset="8-23" type="drug" text="anticholinergic"/><entity id="DrugDDI.d444.s23.e1" origId="s23.p330" charOffset="156-180" type="drug" text="tricyclic antidepressant"/><entity id="DrugDDI.d444.s23.e2" origId="s23.p332" charOffset="186-196" type="drug" text="cimetidine"/><pair id="DrugDDI.d444.s23.p0" e1="DrugDDI.d444.s23.e0" e2="DrugDDI.d444.s23.e1" interaction="false"/><pair id="DrugDDI.d444.s23.p1" e1="DrugDDI.d444.s23.e0" e2="DrugDDI.d444.s23.e2" interaction="false"/><pair id="DrugDDI.d444.s23.p2" e1="DrugDDI.d444.s23.e1" e2="DrugDDI.d444.s23.e2" interaction="true"/></sentence><sentence id="DrugDDI.d444.s24" origId="s24" text="Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine."><entity id="DrugDDI.d444.s24.e0" origId="s24.p347" charOffset="133-143" type="drug" text="cimetidine"/></sentence><sentence id="DrugDDI.d444.s25" origId="s25" text="In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects."><entity id="DrugDDI.d444.s25.e0" origId="s25.p356" charOffset="60-85" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d444.s25.e1" origId="s25.p358" charOffset="107-117" type="drug" text="cimetidine"/><entity id="DrugDDI.d444.s25.e2" origId="s25.p360" charOffset="146-156" type="drug" text="cimetidine"/><pair id="DrugDDI.d444.s25.p0" e1="DrugDDI.d444.s25.e0" e2="DrugDDI.d444.s25.e1" interaction="true"/><pair id="DrugDDI.d444.s25.p1" e1="DrugDDI.d444.s25.e0" e2="DrugDDI.d444.s25.e2" interaction="false"/><pair id="DrugDDI.d444.s25.p2" e1="DrugDDI.d444.s25.e1" e2="DrugDDI.d444.s25.e2" interaction="false"/></sentence><sentence id="DrugDDI.d444.s26" origId="s26" text="Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage."><entity id="DrugDDI.d444.s26.e0" origId="s26.p370" charOffset="0-7" type="drug" text="Alcohol"/><entity id="DrugDDI.d444.s26.e1" origId="s26.p384" charOffset="128-136" type="drug" text="SINEQUAN"/><pair id="DrugDDI.d444.s26.p0" e1="DrugDDI.d444.s26.e0" e2="DrugDDI.d444.s26.e1" interaction="false"/></sentence><sentence id="DrugDDI.d444.s27" origId="s27" text="This is especially important in patients who may use alcohol excessively."><entity id="DrugDDI.d444.s27.e0" origId="s27.p391" charOffset="53-60" type="drug" text="alcohol"/></sentence><sentence id="DrugDDI.d444.s28" origId="s28" text="Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day)."><entity id="DrugDDI.d444.s28.e0" origId="s28.p392" charOffset="0-10" type="drug" text="Tolazamide"/><entity id="DrugDDI.d444.s28.e1" origId="s28.p401" charOffset="104-114" type="drug" text="tolazamide"/><entity id="DrugDDI.d444.s28.e2" origId="s28.p408" charOffset="156-163" type="drug" text="doxepin"/><pair id="DrugDDI.d444.s28.p0" e1="DrugDDI.d444.s28.e0" e2="DrugDDI.d444.s28.e1" interaction="false"/><pair id="DrugDDI.d444.s28.p1" e1="DrugDDI.d444.s28.e0" e2="DrugDDI.d444.s28.e2" interaction="false"/><pair id="DrugDDI.d444.s28.p2" e1="DrugDDI.d444.s28.e1" e2="DrugDDI.d444.s28.e2" interaction="true"/></sentence></document>